Medicare prescription drug costs may change in 2026 — what beneficiaries need to know

Medicare beneficiaries face a Dec. 7 open-enrollment deadline to switch Medicare Advantage or Part D plans; roughly 55 million people are enrolled in standalone Part D or Advantage plans. For 2026, Part D and Medicare Advantage premiums are generally falling and the out-of-pocket prescription cap rises to $2,100 (after which plans cover 100%), while Part B premiums are slated to rise 9.7%. The administration will implement negotiated prices on the first 10 drugs in 2026 (estimated $1.5 billion in beneficiary savings) with additional drug price cuts announced for 2027, underscoring potential revenue and cost implications for insurers and drugmakers and the importance of plan-selection dynamics for retirees.

Analysis

Market structure: Medicare's 2026 changes (lower Part D/Advantage premiums, $2,100 out-of-pocket cap, mandated coverage of negotiated drugs) favor scale players that manage Rx utilization and network pharmacy costs — primary winners are Medicare Advantage managers (UNH, HUM, CVS) and PBMs that can arbitrate price/volume. Branded manufacturers with high Medicare exposure (especially those with drugs on the negotiated lists) lose pricing power; smaller specialty pharma with >20% Medicare revenue are most at risk. Cross-asset: reduced unpredictability of catastrophic drug spend slightly lowers insurers' risk premia (positive for IG credit); limited FX/commodity impact.

Risk assessment: Tail risk includes aggressive expansion of price negotiation scope (bad for large-cap pharma) or legal/regulatory setbacks that delay savings; a low-probability upside is rapid volume growth offsetting price cuts. Immediate (days) effects center on enrollment season flows through Dec 7; short-term (3–12 months) on 2026 premium announcements and plan mix shifts; long-term (2026–2028) on negotiated-price rollouts (notably 2027 Ozempic cut). Hidden dependency: PBM contract terms and formularies that can re-route volume; CMS formulary mandates are the key catalyst.

Trade implications: Favor long, concentrated exposure to large insurers with MA scale (UNH, HUM, CVS) and short pharma names with concentrated Medicare revenue or names on the negotiation lists. Pair trades (long UNH vs short XPH/IBRX/IBB) exploit relative winners. Use defined-risk option structures (bull call spreads on insurers; put spreads on exposed pharma) to limit tail losses. Enter ahead of Dec 7 enrollment changes and scale into positions through Q1 2026 as negotiated-drug lists finalize.

Contrarian angles: Consensus may over-penalize big pharma; volume growth from lower out-of-pocket caps can offset some price declines — therapeutic leaders with broad commercial channels (e.g., diabetes/obesity drugs) may see demand resilience. Historical parallels (prior Part D adjustments) show large-cap pharma pricing power is durable, so avoid indiscriminate shorting of diversified majors. Unintended consequence: insurers could face margin pressure if utilization spikes faster than premium adjustments — monitor utilization and claims trends closely.

Key Decisions for Investors

• Establish a 1.5% long position each in UnitedHealth (UNH) and Humana (HUM) within 30 days; implement 6–12 month bull-call spreads (buy 1.5–2.0% delta calls, sell higher strike) targeting 8–15% upside, stop-loss at -8% per name if enrollment/PMPM margins deteriorate.
• Initiate a 1.0% pair trade: long UNH (1.0%) vs short XPH (SPDR S&P Pharmaceuticals ETF) 0.7% or IBB 0.7% to express MA/insurer outperformance versus broad pharma; close if spread narrows >5% or if CMS announces fewer drugs subject to negotiation than expected.
• Establish a defined-risk bearish option position against Novo Nordisk (NVO) or a high-Medicare-revenue specialty pharma: buy 6–9 month put spread sized 0.75% portfolio risk (e.g., buy 10% OTM put, sell 20% OTM put) and increase to 1.5% if company discloses >20% revenue from negotiated drugs or CMS list inclusion.
• Allocate 2–3% to IG healthcare insurer bonds (e.g., UNH, HUM paper) with 2–5 year maturities to capture tightening credit spreads if MA margin visibility improves; sell/trim exposure if claims inflation >200 bps above consensus in next two quarterly updates.
• Monitor three triggers over next 60 days and act: (1) final CMS 2026 Part D plan counts and premium maps by county (reduce pharma shorts if plan counts drop <5%), (2) CMS negotiated drug list updates (add to shorts if target drugs include issuer), (3) Dec 7 enrollment snapshots (add to MA longs if net inflows > prior-year by +3%).